Multicomponent synthesis of sulfonamides from triarylbismuthines, nitro compounds and sodium metabisulfite in deep eutectic solvents
作者:Xavier Marset、Javier Torregrosa-Crespo、Rosa M. Martínez-Espinosa、Gabriela Guillena、Diego J. Ramón
DOI:10.1039/c9gc01541h
日期:——
Na2S2O5 and nitro compounds in a DeepEutecticSolvent (DES) as a reaction medium is described. Thus, triarylbismuthines are used as reagents for the incorporation of SO2 into organic motifs. The bismuth salts formed as by-products can be easily removed from the crude reaction mixture by precipitation with water, while the use of volatile organic compounds (VOCs) as solvents can be avoided in the entire
描述了一种在深度共晶溶剂(DES)中使用铜催化的方法从三芳基双变异蛋白,Na 2 S 2 O 5和硝基化合物开始可持续合成磺酰胺的方法。因此,将三芳基双突变蛋白用作掺入SO 2的试剂变成有机图案。通过用水沉淀,可以很容易地从粗反应混合物中除去作为副产物形成的铋盐,同时在整个过程中可以避免使用挥发性有机化合物(VOC)作为溶剂。用作溶剂的低共熔混合物已得到充分表征,初步结果证明其毒性低。设计的DES还可以进行新颖的多组分反应,从而节省时间并减少纯化步骤,能源和成本。
Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents
申请人:Jirgensons Aigars
公开号:US20100311741A1
公开(公告)日:2010-12-09
This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of TACE.
Practical chemoselective aromatic substitution: the synthesis of <i>N</i>-(4-halo-2-nitrophenyl)benzenesulfonamide through the efficient nitration and halogenation of <i>N</i>-phenylbenzenesulfonamide
the metal-promoted tandem nitration and halogenation of N-phenylbenzenesulfonamide to synthesize N-(4-halo-2-nitrophenyl)benzenesulfonamide derivatives has been developed. The method shows highly practical chemoselective and functional group compatibility. In addition, it employs insensitive and inexpensive Cu(NO3)2·3H2O, Fe(NO3)3·9H2O, and NH4NO3 as the nitrationreagents, and it provides a direct
[EN] BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS DE L'ACIDE BICYCLOSULFONYLIQUE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
申请人:INHIBOX LTD
公开号:WO2008142376A1
公开(公告)日:2008-11-27
[EN] This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-a Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-a, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in [FR] Cette invention appartient d'une manière générale au domaine des composés thérapeutiques et plus particulièrement, à certain composés de l'acide bicyclosulfonylique (BCSA) qui agissent comme inhibiteurs de l'enzyme de conversion du facteur a de nécrose tumorale (TACE). Ces composés s'avèrent utiles dans le traitement de états médiés par le TNF-a, tels que la polyarthrite chronique évolutive; l'inflammation; le psoriasis; le choc septique; le rejet de greffe; la cachexie; l'anorexie; l'insuffisance cardiaque congestive; les maladies inflammatoires du SNC; l'affection abdominale inflammatoire; la résistance à l'insuline; l'infection par le VIH; le cancer; la bronchopneumopathie chronique obstructive et l'asthme. L'invention porte également sur des compositions pharmaceutiques comprenant de tels composés et sur l'utilisation de tels composés et compositions, tant in vitro qu'in vivo, pour l'inhibition du TACE et pour le traitement d'états améliorées par l'inhibition du TACE.
Metal-free one-pot synthesis of N-arylsulfonamides from nitroarenes and sodium sulfinates in an aqueous medium
metal-free one-pot two-step synthesis of sulfonamides from readily available nitroarenes and sodium arylsulfinates in a mixture of methanol and water has been developed. In this procedure, the aryl amines were produced in situ by the reduction of nitroarenes mediated by diboronic acid, and then coupled with sodium arylsulfinates in the presence of iodine. A series of N-arylsulfonamides with various functional